Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Scotland

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

JAK inhibitor approved for use in moderate-to-severe RA

- PMLiVE

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial

- PMLiVE

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours

- PMLiVE

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

Treatment and prevention of cardiovascular disease

The potential of next generation omega-3 fatty acids

- PMLiVE

GSK signs collaboration deal with Ligand targeting neurological disorders

This is the latest in a string of pipeline deals announced by GSK

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Amgen aims for first KRAS inhibitor approval in the US

Sotorasib is a potential treatment for advanced KRAS G12C-mutated NSCLC

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links